Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H10O4 |
Molecular Weight | 242.2268 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(OOC(=O)C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=OMPJBNCRMGITSC-UHFFFAOYSA-N
InChI=1S/C14H10O4/c15-13(11-7-3-1-4-8-11)17-18-14(16)12-9-5-2-6-10-12/h1-10H
Molecular Formula | C14H10O4 |
Molecular Weight | 242.2268 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Benzoyl peroxide (BPO) is an organic compound in the peroxide family. It consists of two benzoyl groups bridged by a peroxide link. It is one of the most important organic peroxides in terms of applications and the scale of its production. Benzoyl peroxide is used as an acne treatment, for bleaching hair and teeth. Adverse reactions are: dryness and urticarial reaction, contact dermatitis, application site burning, application site irritation and skin irritation.
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
10 % 2 times / day multiple, topical Highest studied dose Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy, 20 years n = 25 Health Status: unhealthy Condition: acne vulgaris Age Group: 20 years Sex: M+F Population Size: 25 Sources: |
Other AEs: Peeling, Erythema... Other AEs: Peeling (moderate, 55%) Sources: Erythema (moderate, 30%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Erythema | moderate, 30% | 10 % 2 times / day multiple, topical Highest studied dose Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy, 20 years n = 25 Health Status: unhealthy Condition: acne vulgaris Age Group: 20 years Sex: M+F Population Size: 25 Sources: |
Peeling | moderate, 55% | 10 % 2 times / day multiple, topical Highest studied dose Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy, 20 years n = 25 Health Status: unhealthy Condition: acne vulgaris Age Group: 20 years Sex: M+F Population Size: 25 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Current issues in antimicrobial therapy for the treatment of acne. | 2001 |
|
Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. | 2001 |
|
Evaluation of certain food additives and contaminants. | 2001 |
|
Interleukin-6 expression by osteoblast-like MG63 cells challenged with four acrylic bone cements. | 2001 |
|
Characterization of powder components of commercial bone cements. | 2001 Dec |
|
A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. | 2001 Jan-Feb |
|
Analysis for organic residues from aids to polymerization used to make plastics intended for food contact. | 2001 May |
|
The radical-chain addition of aldehydes to alkenes by the use of N-hydroxyphthalimide (NHPI) as a polarity-reversal catalyst. | 2001 Nov 21 |
|
[Optimized polymethyl methacrylate-embedding enables exact section examination of the femur with an uncemented femoral stem]. | 2001 Nov-Dec |
|
The stability of benzoyl peroxide by isothermal microcalorimetry. | 2001 Oct 4 |
|
Characterization of new acrylic bone cements prepared with oleic acid derivatives. | 2002 |
|
Consideration on the formulation of benzoyl peroxide at ambient temperature: choice of non-polar solvent and preparation of submicron emulsion gels. | 2002 Aug |
|
Studies on MMA-tBB resin. I. Comparison of TBB and other initiators in the polymerization of PMMA/MMA resin. | 2002 Dec |
|
Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. | 2002 Feb |
|
Scavenging of benzylperoxyl radicals by carotenoids. | 2002 Feb |
|
The effect of benzoyl peroxide and benzoyl peroxide/erythromycin combination on the antioxidative defence system in papulopustular acne. | 2002 Jan-Feb |
|
A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. | 2002 Jul |
|
Study of resin-bonded calcia investment: part 2. Effect of titanium content on the dimensional change of the investment. | 2002 Jun |
|
Occupational dermatoses among fibreglass-reinforced plastics factory workers. | 2002 Jun |
|
Oral toxicity of topical preparations. | 2002 Mar |
|
Benzoyl peroxide: a history of early research and researchers. | 2002 Mar |
|
Contact dermatitis from benzoyl peroxide in dental prostheses. | 2002 Mar |
|
Platelet release of transforming growth factor-beta and beta-thromboglobulin after in vitro contact with acrylic bone cements. | 2002 Mar |
|
Formation of a bioconjugate composed of hemin, smectite, and quaternary ammonium chloride that is soluble and active in hydrophobic media. | 2002 Mar-Apr |
|
Clindoxyl gel for the treatment of acne vulgaris. | 2002 May |
|
Impact of components of denture acrylic resin on gingival cell growth and sensitivity to Candida albicans adhesion. | 2002 Oct |
|
Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. | 2002 Sep |
|
Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. | 2002 Sep |
|
Iron augments stage-I and stage-II tumor promotion in murine skin. | 2002 Sep 26 |
|
Topical acne drugs: review of clinical properties, systemic exposure, and safety. | 2003 |
|
Inhibition of benzoyl peroxide and ultraviolet-B radiation induced oxidative stress and tumor promotion markers by cycloartenol in murine skin. | 2003 |
|
Efficacy and safety of stabilised hydrogen peroxide cream (Crystacide) in mild-to-moderate acne vulgaris: a randomised, controlled trial versus benzoyl peroxide gel. | 2003 |
|
Guidelines for the management of acne vulgaris in adolescents. | 2003 |
|
Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery. | 2003 Apr |
|
Management of non-neoplastic ovarian cysts with sclerotherapy. | 2003 Apr |
|
Tandem N-alkylation-C-allylation reaction of alpha-imino esters with organoaluminums and allyltributyltin. | 2003 Apr 2 |
|
Patch testing with the irritant sodium lauryl sulfate (SLS) is useful in interpreting weak reactions to contact allergens as allergic or irritant. | 2003 Feb |
|
Implications of the BEST study. | 2003 Feb |
|
The BEST study: results according to prior treatment. | 2003 Feb |
|
The BEST study: evaluating efficacy by selected demographic subsets. | 2003 Feb |
|
Overall results of the BEST study following treatment of patients with mild to moderate acne. | 2003 Feb |
|
Study design and selection criteria in the BEST study. | 2003 Feb |
|
Improving patient satisfaction and acne severity in patients with mild to moderate acne: the BEST study. | 2003 Feb |
|
Management of acne. | 2003 Jan |
|
Progressive iron overload enhances chemically mediated tumor promotion in murine skin. | 2003 Jan 15 |
|
A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. | 2003 Jan-Feb |
|
Studies on MMA-TBB resin II. The effect of dual use of TBB and other initiators on polymerization of PMMA/MMA resin. | 2003 Mar |
|
Fox-Fordyce disease. | 2003 Mar |
|
Functionalization of carbon nanotubes by free radicals. | 2003 May 1 |
|
Improved one-pot synthesis of styryl tetrahydrofurans and cyclohexanes by radical addition to beta-nitrostyrenes in the presence of benzoyl peroxide. | 2003 May 9 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Benzamicin gel in combination with adapalene (instead of erythromycin) have to be applied once daily after washing.
Benzamicin gel should be applied twice daily.
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/26806150
The minimum inhibitory concentrations of Benzoyl peroxide were 128 or 256 ug/mL against all isolates of P. acnes
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:54:24 UTC 2022
by
admin
on
Fri Dec 16 16:54:24 UTC 2022
|
Record UNII |
W9WZN9A0GM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
E-928
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
13.4
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
CODEX ALIMENTARIUS (GSFA) |
E-928
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
WHO-ATC |
D10AE01
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
CFR |
21 CFR 333.310
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
EPA PESTICIDE CODE |
128964
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
CFR |
21 CFR 184.1157
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
WHO-VATC |
QD10AE01
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
||
|
WHO-ATC |
D10AE51
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB122302
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
M2389
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | Merck Index | ||
|
W9WZN9A0GM
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
C47411
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
Benzoyl Peroxide
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
BENZOYL PEROXIDE
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
E-928
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
CHEMBL1200370
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
372
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
BENZOYL PEROXIDE
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | Description: A white, amorphous or granular powder. Solubility: Practically insoluble in water; soluble in acetone R; soluble in dichloromethane R with separation of water; slightlysoluble in ethanol (~750 g/l) TS. Category: Keratolytic agent. Storage: Hydrous Benzoyl peroxide should be kept in a container that has been treated to reduce static discharge and that has a device for the release of excess pressure. Store at a temperature between 2 and 8 ?C, protected from light. Additional information: CAUTION: Hydrous Benzoyl peroxide may explode at temperatures higher than 60 ?C or if its water content is too low. It may burst into flame in the presence of reducing substances. Unused material must not be returned to the original container but destroyed by treating with sodium hydroxide (~80 g/l) TS to a point where no iodine is liberated after acidifying with hydrochloric acid (~70 g/l) TS and adding a crystal of potassium iodide R. Hydrous Benzoyl peroxide loses water rapidly on exposure to air. It must be handled with care, avoiding contact with the skin and mucous membranes and inhalation of airborne particles. | ||
|
202-327-6
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
7187
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
328
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
W9WZN9A0GM
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
DUAC
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | APPROVED MARCH 2015 | ||
|
SUB11742MIG
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
D001585
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
SUB13020MIG
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
DB09096
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
675
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
DTXSID6024591
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
671
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | |||
|
1418
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY | RxNorm | ||
|
94-36-0
Created by
admin on Fri Dec 16 16:54:24 UTC 2022 , Edited by admin on Fri Dec 16 16:54:24 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|